T
Therese S. Geraci
Researcher at Veterans Health Administration
Publications - 6
Citations - 5316
Therese S. Geraci is an academic researcher from Veterans Health Administration. The author has contributed to research in topics: Chlorthalidone & Randomized controlled trial. The author has an hindex of 5, co-authored 6 publications receiving 5129 citations.
Papers
More filters
Journal ArticleDOI
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Curt D. Furberg,Jackson T. Wright,Barry R. Davis,Jeffrey A. Cutler,Michael H. Alderman,Henry R. Black,William C. Cushman,Richard H. Grimm,L. Julian Haywood,Frans H. H. Leenen,Suzanne Oparil,Jeffrey L. Probstfield,Paul K. Whelton,Chuke Nwachuku,David Gordon,Michael A. Proschan,Paula Einhom,Charles E. Ford,Linda B. Piller,I. Kay Dunn,David C. Goff,Sara L. Pressel,Judy Bettencourt,Barbara DeLeon,Lara M. Simpson,Joe Blanton,Therese S. Geraci,Sandra M. Walsh,Christine Nelson,Mahboob Rahman,Anne Juratovac,Robert Pospisil,Lillian Carroll,Sheila Sullivan,Jeanne Russo,Gail Barone,Rudy Christian,Sharon Feldman,Tracy Lucente,David A. Calhoun,Kim Jenkins,Peggy McDowell,Janice Johnson,Connie Kingry,Juan Alzate,Karen L. Margolis,Leslie Ann Holland-Klemme,Brenda Jaeger,Jeff D. Williamson,Gail T. Louis,Pamela Ragusa,Angela Williard,R. L Sue Ferguson,Joanna Tanner,John H. Eckfeldt,Richard S. Crow,John Pelosi +56 more
TL;DR: Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive and should be preferred for first-step antihypertensive therapy.
Journal ArticleDOI
Recruitment Strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
Connie Kingry,Arnaud Bastien,Gillian L. Booth,Therese S. Geraci,Brenda Kirpach,Laura C. Lovato,Karen L. Margolis,Yves Rosenberg,JoAnne M. Sperl-Hillen,Laura Vargo,Jeff D. Williamson,Jeffrey L. Probstfield +11 more
TL;DR: The ACCORD vanguard and main trial recruitment activities, including strategy implementation, screening procedures, randomization results, problems encountered, and lessons learned are described.
Journal ArticleDOI
Patients' explanatory models for heart failure and COPD exacerbations
TL;DR: The findings provide a basis for understanding the EMs of persons with HF or COPD as an initial step in making health care more relevant.
Journal ArticleDOI
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Sara L. Pressel,Barry R. Davis,Jackson T. Wright,Therese S. Geraci,Connie Kingry,Charles E. Ford,Linda B. Piller,Judy Bettencourt,Barbara Kimmel,Christine Lusk,Heather Parks,Lara M. Simpson,Chuke Nwachuku,Curt D. Furberg +13 more
TL;DR: The steps involved in the orderly closeout of one arm of ALLHAT are discussed, which included provisional preparations; the actual decision process; establishing a timetable; and monitoring the closeout process.
Journal ArticleDOI
Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Vasilios Papademetriou,Linda B. Piller,Charles E. Ford,David Gordon,Thomas J. Hartney,Therese S. Geraci,Efrain Reisin,Brian Montgomery Sumner,Nathan D. Wong,Chuke Nwachuku,Puneet Narayan,L. Julian Haywood,Gabriel B. Habib +12 more
TL;DR: The success of the randomization of this large, diverse population and the differences in the lipid distributions among its subgroups will allow further understanding of optimal lipid‐lowering treatment.